Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13
Benzinga Newsdesk 13 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and raises the price target from $10 to $13.
Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and raises the price target from $10 to $13.